Vibegron is the active pharmaceutical ingredient in Gemtesa, a medication used to treat overactive bladder (OAB) [1]. Gemtesa is the brand name under which vibegron is marketed [1]. Therefore, vibegron is not a generic for Gemtesa; rather, Gemtesa is the brand name for vibegron [1].
When will Gemtesa lose its exclusivity?
The United States Patent for Gemtesa (vibegron) is set to expire in 2027 [2]. However, patent litigation can impact the timeline for generic entry [3].
What is the difference between a brand-name drug and a generic drug?
Brand-name drugs, like Gemtesa, are developed by pharmaceutical companies and sold under a specific trademarked name. Generic drugs contain the same active ingredient as the brand-name drug and are generally considered to be therapeutically equivalent [4]. They are typically approved by regulatory agencies after the patents on the brand-name drug expire [4].
What is vibegron used for?
Vibegron is prescribed to treat adults with overactive bladder (OAB), which is characterized by symptoms such as urinary urgency, frequency, and urge incontinence [1]. It works by relaxing the detrusor muscle in the bladder, which helps to increase bladder capacity and reduce the involuntary contractions that cause OAB symptoms [1].